MedElevator Войти в исследования
← Поиск публикаций

DOI 10.11406/rinketsu.65.135

Медицинская библиотека · [Rinsho ketsueki] The Japanese journal of clinical hematology · 2024

[Safety and efficacy of 7-day administration of azacitidine and venetoclax combination therapy (7+7 therapy)].

Osada Yuki, Kanai-Sudo Hikari, Mizuki Taro, Tanosaki Sakae, Suzuki Ken

Аннотация на английскомСтатьяПеревод в очереди

Аннотация

Acute myelogenous leukemia (AML) has a poor prognosis in patients who are ineligible for intensive chemotherapy. The combination of azacitidine and venetoclax has been shown to have high overall efficiency and remission rates, even in patients ineligible for aggressive chemotherapy. However, myelosuppression is often prolonged after treatment, and infection can also occur. Severe myelosuppression is often addressed by dose titration, but specific dose titration methods have not been clarified. We used the standard induction therapy with azacitidine plus venetoclax, and if blasts decreased to 20% or less, switched to 7+7 therapy to shorten venetoclax to 7 days starting from the next cycle. In the 19 patients we treated (median age 80 years), response rate above MLFS was 100%, CR 57.9%, CRc (CR+CRi) 78.8%, median OS 693 days, median PFS 458 days, and median OS was not reached in previously untreated patients. This indicates that 7+7 is a highly effective and well-tolerated treatment.

Для цитирования: Osada Yuki, Kanai-Sudo Hikari, Mizuki Taro, Tanosaki Sakae, Suzuki Ken. [Safety and efficacy of 7-day administration of azacitidine and venetoclax combination therapy (7+7 therapy)].. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2024. DOI: 10.11406/rinketsu.65.135.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.